Thu, Jul 24, 2014, 6:59 AM EDT - U.S. Markets open in 2 hrs 31 mins

Recent

% | $
Click the to save as a favorite.

Dynavax Technologies Corporation Message Board

outboard.jack 129 posts  |  Last Activity: 21 hours ago Member since: Nov 26, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Patent Publication number WO2014052931 A1

    by adamsribmarrow Jul 22, 2014 10:05 PM
    outboard.jack outboard.jack 21 hours ago Flag

    Ad,

    It's the Science

    The TLR science has been proven valid.

    The presence of Merck, GSK and AstraZ ALL validate that the TLR science is genuine.

    Why would GSK promise $800MM on a science that was UN-VALIDATED, UNSAFE, UNPROVEN?

    AZ has not left either and DVAX did nothing on their projects from 2009 until 2013.

    Who WOULD stay 4 years waiting around for something which might not be VALID?

    Dynavax gets HEP-LISA-V, FDA Approved the SCIENCE is worth BILLIONS

  • outboard.jack outboard.jack Jul 18, 2014 2:42 PM Flag

    TYPO
    There is more to Dynavax (than) we Know?

  • outboard.jack outboard.jack Jul 18, 2014 2:37 PM Flag

    Say Doob,
    Do you know about SuperVax
    That is sitting on a shelf
    Or about our shelved universal Flu Vac

    SUPERVAX

    In April 2006, we completed the acquisition of Rhein Biotech GmbH, which we refer to as Dynavax Europe. As a result, we acquired a hepatitis B vaccine called SUPERVAX that has been tested in more than 600 subjects and has demonstrated safety and 99% seroprotection when administered on a two-dose schedule. SUPERVAX was launched in Argentina in December 2006 and is approved for marketing and sales through a third party partner. We intend to continue registration activities for SUPERVAX as a two-dose vaccine for adolescents for commercialization through partners in select countries outside of North America and Europe

    There is more that we know
    And who knows when news hits be Good or Bad *

  • outboard.jack outboard.jack Jul 18, 2014 10:04 AM Flag

    List is a little dated but action or information about other candidates ?
    You think you know ?

  • outboard.jack outboard.jack Jul 18, 2014 9:36 AM Flag

    Dynavax's pipeline consists of five drug candidates: Heplisav, DV1179, AZ1419, SD-101, and DV230.

    Programs

    Heplisav
    Hepatitis B vaccine
    Phase 3 completed, NDA filed

    DV1179
    Autoimmune/inflammation
    Phase 1

    AZ1419
    Asthma/COPD
    Phase 1

    SD-101
    Cancer immunotherapy
    Phase 1

    DV230
    Nanoparticle adjuvant technology
    Pre-clinical

    MIA
    SuperVax
    Universal Flu Vax

  • outboard.jack outboard.jack Jul 18, 2014 9:26 AM Flag

    Lupus Q3

    POM study in Lupus to be completed in Q3 2014
    GSK has option to license the program after POM data
    UP to 125 Million in renaming milestones plus royalties

    GSK can exercise its exclusive option to license each program. If GSK exercises an option, GSK would carry out further development and commercialization of the corresponding products. If GSK exercises their option on the Lead TLR 7/9 program, then we are eligible to receive payments of up to approximately $125 million, comprised of contingent option exerc ise payments and additional payments based on GSK’s achievement of certain development, regulatory and commercial objectives

  • Reply to

    In two weeks...

    by kentwu28 Jul 16, 2014 4:10 PM
    outboard.jack outboard.jack Jul 17, 2014 1:48 PM Flag

    Yes

  • Reply to

    In two weeks...

    by kentwu28 Jul 16, 2014 4:10 PM
    outboard.jack outboard.jack Jul 17, 2014 9:22 AM Flag

    for mass vaccination programmes offered by international health organizations, such as UNICEF, for newborn children and infants.

    Rhein Biotech has granted numerous research licenses and commercial licenses for the use of its Hansenula technology to companies including Serum Institute of India, Wockchard Limited (India) and Aventis Pasteur.

    On the basis of its 3-dose Hepatitis B technology, the biotech company additionally developed a 2-dose Hepatitis B vaccine with a much faster onset of immuno-protection. The new vaccine will enter clinical trials at the end of 2006.

    Rhein Biotech has become the third largest global producer of Hepatitis B vaccines worldwide. The success of Hansenula technology enabled the company to list on the Frankfurt Stock Exchange in 1999.

    In addition to Hepatitis B vaccines, Rhein Biotech has developed production technologies for three other biopharmaceuticals, all based on Hansenula technology: Interferon alpha-2a, human insulin and Hirudin. The company’s licensees have successfully introduced the products into the market.

    Further biopharmaceuticals may yet be developed using the technology. In the meantime, this invention has helped combat the spread of Hepatitis B worldwide through the development of a cost-effective vaccine production process, thanks to the work of scientists at Rhein Biotech.

  • Reply to

    In two weeks...

    by kentwu28 Jul 16, 2014 4:10 PM
    outboard.jack outboard.jack Jul 17, 2014 8:53 AM Flag

    The Market is very limited ?

    According to World Health Organization estimates, more than one third of the world’s population is infected with Hepatitis B. Worldwide, 350 million people are chronic carriers of the virus. The disease can result in liver cirrhosis or cancer and in some cases, can be life-threatening. It can be transmitted by sexual contact, shared needles, or contaminated blood products. Doctors, or those working with blood, are at risk.

    Prophylactic vaccination is generally considered to be the best means to control the spread of this severe, viral liver disease. However, existing recombinant vaccines were considered too expensive for mass vaccination programmes until scientists came up with a new, cost-effective vaccine technology.

    The scientists, namely Zbigniew Janowicz, and Professor Cornelius Hollenberg, invented a process for the production of foreign proteins in Hansenula yeast. The technology allows for a high-yield production process. The result is a pure vaccine, which is free of pathogens and can be safely administered without using a needle. The method is deemed essential for the development of recombinant gene expression and processes for the production of proteins, especially active pharmaceutical ingredients.

    The Hansenula technology was granted a patent in 1994. A number of commercial biopharmaceutical and biotech applications now use Hansenula polymorpha yeast expression technology. The method is acknowledged as an industrial standard for protein production.

    The invention of Hansenula technology enabled the introduction of standard vaccination programmes to counter the spread of Hepatitis B disease worldwide. Rhein Biotech GmbH, a spin-off of the University of Düsseldorf, first developed a 3-dose Hepatitis B vaccine using the method at the start of the 1900s. The company then licensed the technology to Korea Green Cross, one of its subsidiaries. Korea Green Cross became the first company to offer an affordable Hepatitis B vac

  • Reply to

    Seeking The Truth About The RS

    by pylesm Jul 15, 2014 10:39 PM
    outboard.jack outboard.jack Jul 16, 2014 9:06 AM Flag

    Rave,

    LOL,
    DVAX is your DRUG of choice *

  • Reply to

    My problem with the reverse split business

    by ctic_neutral Jul 14, 2014 1:07 PM
    outboard.jack outboard.jack Jul 14, 2014 1:50 PM Flag

    Straight from the Horse's mouth

    From the Q

    Because only 0.1% of the authorized shares under our Certificate of Incorporation remain available for issuance, we require additional available authorized shares of common stock to provide for any potential future stock issuances to raise capital, (effect acquisitions) and/or provide equity incentives to our employees. At present, we do not have any plans or arrangements to issue additional shares of common stock other than shares currently reserved for issuance under our existing equity incentive plans and upon conversion of our outstanding Series B convertible preferred stock and warrants

  • Reply to

    No spec talk on the sec filing 6/20

    by jerschlo Jul 14, 2014 1:38 PM
    outboard.jack outboard.jack Jul 14, 2014 1:44 PM Flag

    Read thru them the day they were posted nothing new.
    Did you see something?

  • outboard.jack by outboard.jack Jul 14, 2014 9:25 AM Flag

    4.00 Calls getting some action *

  • Reply to

    GSK. SEX LIES & VIDEO

    by outboard.jack Jun 29, 2014 6:18 PM
    outboard.jack outboard.jack Jul 14, 2014 7:22 AM Flag

    China indicts US, British corporate investigators
    China indicts US, British corporate investigators for illegally obtaining private information
    By Gillian Wong, Associated Press
    16 minutes ago

    BEIJING (AP) -- Chinese authorities have indicted British and American investigators hired by GlaxoSmithKline on charges of illegally obtaining and selling private information, state media reported Monday, as the Briton blamed the pharmaceutical company for misleading and using him.

    British investigator Peter Humphrey and his wife Yingzeng Yu, a U.S. citizen, were charged in Shanghai's No. 1 Intermediate People's Court, the official Xinhua News Agency said. It said this is the first time foreigners have faced such charges.

    Humphrey, 58, and Yu, 61, are part of an industry of investigators who help corporate clients screen potential partners and employees or watch for embezzlement and other employee misconduct.

    Their arrest last year coincided with a Chinese investigation of accusations that GlaxoSmithKline paid bribes to doctors and officials to use its medications. Glaxo said it hired Yu and Humphrey last year to investigate a security breach involving a top manager.

    The indictment received prominent coverage in China. Reports by state broadcaster CCTV showed Humphrey and Yu being separately interviewed by Chinese reporters. They were shown seated and wearing orange vests that are typical uniforms of detainees as they spoke to reporters.

    The couple, who ran a Shanghai firm, ChinaWhys Ltd., were accused of illegally selling a "huge amount" of personal information on Chinese citizens, Xinhua said. It said that included home addresses, information about family members, details about real estate and vehicles and records of travelers entering and leaving the country.

    Prosecutors say they obtained such information by illegally buying it from others as well as with hidden cameras or by following people, Xinhua said. It said they would sell the reports to clients that were mainly multinational companies in China such as GSK China.

    In Chinese media reports on Monday, Humphrey said he was contacted in April 2013 by GSK's then-China manager, Mark Reilly, who wanted him to find out who leaked allegations of bribery at the firm to Chinese authorities and senior executives at the firm.

    Reilly, who is British, is at the center of a major investigation into corruption in China's medical industry. In May, he was accused of leading a sprawling scheme to bribe doctors and hospitals to use GSK's drugs. Reilly's case has been turned over to prosecutors.

    Humphrey said on state television that he found out during his investigation that the bribery claims were true and if he had known that earlier he would not have carried out the probe. Humphrey said he felt "betrayed and used" by the pharmaceutical firm.

    In a written response to a request for comment, Glaxo cited a July 3 statement that said Humphrey and Yu's firm was hired in April 2013 to investigate "a serious breach of privacy and security related to" Reilly.

    "They were not hired to investigate the substance of the allegations of misconduct made by the whistleblower," the company said in an email.

    The British Embassy in Beijing said it was providing consular help to Humphrey and his family and have told Chinese authorities they would like to attend the trial, which the court has said will be closed. A trial date hasn't been announced yet.

    "We have made clear to the Chinese authorities that we would like Embassy staff to attend the trial and the need for a transparent and fair process," the embassy said in an emailed response to questions.

  • Reply to

    Reverse split after the fact

    by outboard.jack Jul 13, 2014 10:13 PM
    outboard.jack outboard.jack Jul 14, 2014 6:46 AM Flag

    Kia
    For me it's a hold
    If I didn't own any it would be a Buy

  • outboard.jack by outboard.jack Jul 13, 2014 10:13 PM Flag

    As  we rise to the 4.00 area over the next 12 months  ( without any AE. )
    Company implements a 10 for 1 and " If we hit"  you have a 80.00 dollar stock

    A 1 for 10 would make for a 24 Million share float 

    You do realize that 70 to 80 % is held by institutions and if it is a high dollar stock that will increase. 
    Shares will be 
    Hard to borrow 
    And Hard to get

    This is the perfect storm  *

  • Reply to

    Update !

    by outboard.jack Jul 10, 2014 7:42 PM
    outboard.jack outboard.jack Jul 11, 2014 12:05 PM Flag

    O & BUY under .50 *

  • Reply to

    Update !

    by outboard.jack Jul 10, 2014 7:42 PM
    outboard.jack outboard.jack Jul 11, 2014 11:49 AM Flag

    Rode SIRI from .35 to 2.85 been out for for some TIME *
    SIRI bought me Two rent homes on MAUI
    Needless to say I'm a LIFE TIME subscriber to SIRI

  • outboard.jack by outboard.jack Jul 10, 2014 7:42 PM Flag

    Updated Information of full time Dasher clown working 24/7 Bashing kred :
    aq8mar

    Please note, this - Loser Clown is most probably Short the stock now after losing his A $$
    In KRED.

    Like all Clowns he is here to entertain only
    Please do your own DD*

  • Reply to

    Soon

    by mben_56 Jul 8, 2014 10:58 PM
    outboard.jack outboard.jack Jul 10, 2014 1:40 PM Flag

    What up World *

DVAX
1.410.00(0.00%)Jul 23 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Facebook, Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT
Xilinx Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT